Why treat non-alcoholic fatty liver disease?
https://doi.org/10.21518/2079-701X-2013-10-89-93
Abstract
The article considers the problem of non-alcoholic fatty liver disease, analyzes the main etiopathogenic aspects and risk factors such as obesity, insulin resistance and other. The treatment regimen with pathogenically relevant drugs, including the new generation hepatorpotectors, is discussed.
About the Authors
I. G. Pakhomova
Northwestern State Medical University named after I.I. Mechnikov, St. Petersburg
Russian Federation
Russian Federation
Y. P. Uspenskiy
St. Petersburg State Medical University named after I.P. Pavlov
Russian Federation
Russian Federation
References
1. Angulo P. Nonalcoholic fatty liver disease//N Engl J Med. 2002; 346: 1221-1231. http://www.nejm.org/doi/full/10.1056/NEJMra011775;
2. Kotronen A., Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome // Arterioscler Thromb Vasc Biol. 2008; 28: 27-38. http://atvb.ahajournals.org/concent/28/1/27
3. Leuschner U., James O.F.W., Dancygier H. Steatohepatitis (NASH and ASH): Dr. Falk Pharma Gmbh, 2005; 35.
4. Драпкина О.М., Гацолаева Д.С., Ивашкин В.Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома// Российские медицинские вести. 2010; 2: 72–78
5. Bellentani S., Pozzato G. Clinical course and risk factors of hepatitis C virus related disease in general population: report from the Dyonysos study // Gut. 1999; 44 (3): 874–880
6. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E. The metabolic syndrome and total cardiovascular disease mortality in middle–aged men / //JAMA. 2002; 4. 288 (21): 2709–2716
7. Буеверов А.О., Ешану В.С., Маевская М.В., Ивашкин В.Т Эссенциальные фосфолипиды в комплексной терапии стеатогепатита смешанного генеза // Клинические перспективы гастроэнтерологии, гепатологии. 2008; 1: 17–22.
8. Полунина Т.Е. Неалкогольная жировая болезнь печени – мультифакторная патология// Мед.вестник 2013;13-14: 11-13
9. Dongiovanni P., Valenti L., Rametta R. et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease // Gut. 2010, 59: 267–273
10. Solis Herruzo J.A, Garcia Ruiz I., Perez Carreras M., Munoz Yague M.T. Non–alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction // Rev. Esp. Enferm. Dig. 2006; 98 (11): 844–874
11. Мехтиев С.Н., Гриневич В.Б., Кравчук Ю.А. Неалкогольная жировая болезнь печени: клиника, диагностика и лечение // Лечащий врач. 2008;2: 23–26
12. Targher G., Bertolini L., Padovani R. et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease// Diabetes Care. 2006; 29: 1325–1330
13. Chen S.H., He F., Zhou H.L., Wu H.R., Xia C., Li Y.M. Relationship between nonalcoholic fatty liver disease and metabolic syndrome// Journal of Digestive Diseases. 2011; 12: 125–130
14. Драпкина О.М., Смирин В.И., Ивашкин В.Т. Патогенез, лечение и эпидемиология НАЖБП – что нового? Эпидемиология в России // РМЖ. 2011; 28: 1717
15. Goland S., Shimoni S., Zornitzki T. et al Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment// J Clin Gastroenterol. 2006; 40: 949-955
16. Targher G., Day C.P., Bonora E. Cardiovascular Disease in Patient with Nonalcoholic Fatty Liver Disease // N Engl J Med. 2010; 363: 1341-1350
17. Аронов Д.М. Статины снижают смертность и улучшают течение атеросклеротических заболеваний. Cons. Med. 2001; 1: 10
18. Chang C. Y., Argo C. K., Al-Osaimi A. M., Caldwell S. H. Therapy of NAFLD: antioxidants and cytoprotective agents // J Clin Gastroenterol. 2006, 40 (Suppl 1): S51–S60
19. Simopuolos AP. The importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. // Exp Biol Med (Maywood)., 2008, 233; 6:674-688
20. Бакулин И.Г., Сандлер Ю.Г. Гиполипидемическая терапия и печень// Российские Медицинские Вести 2012. Том XVII;1: 43-51
Review
For citations:
Pakhomova IG, Uspenskiy YP. Why treat non-alcoholic fatty liver disease? Meditsinskiy sovet = Medical Council. 2013;(10):89-93. (In Russ.) https://doi.org/10.21518/2079-701X-2013-10-89-93
Views:
399
Email this article 